Monopar Therapeutics Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | -48.1% | -48.1% | -44.4% |
| FY2022 | -104.2% | -104.2% | -79.5% |
| FY2023 | -150.4% | -150.4% | -114.4% |
| FY2024 | -28.3% | -28.3% | -25.9% |
| FY2025 | -10.0% | -10.0% | -9.7% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | -48.1% | -48.1% | -44.4% |
| FY2022 | -104.2% | -104.2% | -79.5% |
| FY2023 | -150.4% | -150.4% | -114.4% |
| FY2024 | -28.3% | -28.3% | -25.9% |
| FY2025 | -10.0% | -10.0% | -9.7% |